One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
JAMA Dermatology.
doi : 10.1001/jamadermatol.2023.4008
Volume 160(11) pgs. 1147-1257 November 2024
Clinical Application of New Risk-Based Cancer Screening in Patients With Dermatomyositis.
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.
Global Antimicrobial Susceptibility Patterns of Staphylococcus aureus in Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia: A Phase 3 Randomized Clinical Trial.
Bullous Pemphigoid Severity and Levels of Antibodies to BP180 and BP230: A Systematic Review and Meta-Analysis.
Melanoma Incidence and Mortality Trends Among Patients Aged 59 Years or Younger in Sweden.
Low-Dose Metformin and Profibrotic Signature in Central Centrifugal Cicatricial Alopecia.
Inherited Basaloid Neoplasms Associated With SUFU Pathogenic Variants.
Cost and Cost-Effectiveness of the Management Strategies of Chronic Urticaria: A Systematic Review.
Precocious Puberty Among Children and Adolescents With Hidradenitis Suppurativa.
Application of Risk-Based Cancer Screening in Patients With Dermatomyositis.
Treatment of Pembrolizumab-Induced Mucocutaneous Lichen Planus With Metronidazole.
Treatment of Annular Elastolytic Giant Cell Granuloma With Tofacitinib.
Estimating Costs in Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa.
Factors Driving the Risk of Cognitive Impairment in Children With Atopic Dermatitis.
Estimating Costs in Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa-Reply.
Factors Driving the Risk of Cognitive Impairment in Children With Atopic Dermatitis-Reply.
